Generic placeholder image

Current Pharmaceutical Design

Author(s): Yinhong Zhang, Jing He, Lifeng Xiang, Xinhua Tang, Shiyu Wang, Aoyu Li, Chaoyan Wang, Li Li* and Baosheng Zhu*

DOI: 10.2174/0113816128288504240321041408

DownloadDownload PDF Flyer Cite As
Molecular Mechanisms of Medicinal Plant Securinega suffruticosa-derived Compound Securinine against Spinal Muscular Atrophy based on Network Pharmacology and Experimental Verification

Page: [1178 - 1193] Pages: 16

  • * (Excluding Mailing and Handling)

Abstract

Background: Spinal Muscular Atrophy (SMA) is a severe motor neuronal disorder with high morbidity and mortality. Securinine has shown the potential to treat SMA; however, its anti-SMA role remains unclear.

Objective: This study aims to reveal the anti-SMA mechanisms of securinine.

Methods: Securinine-associated targets were acquired from Herbal Ingredients' Targets (HIT), Similarity Ensemble Approach (SEA), and SuperPred. SMA-associated targets were obtained from GeneCards and Dis- GeNET. Protein-protein Interaction (PPI) network was constructed using GeneMANIA, and hug targets were screened using cytoHubba. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed using ClusterProfifiler. Molecular docking was conducted using Pymol and Auto- Dock. In vitro assays were used to verify the anti-SMA effects of securinine.

Results: Twenty-six intersection targets of securinine and SMA were obtained. HDAC1, HDAC2, TOP2A, PIK3R1, PRMT5, JAK2, HSP90AB1, TERT, PTGS2, and PAX8 were the core targets in PPI network. GO analysis demonstrated that the intersecting targets were implicated in the regulation of proteins, steroid hormones, histone deacetylases, and DNA transcription. KEGG analysis, pathway-pathway, and hub target-pathway networks revealed that securinine might treat SMA through TNF, JAK-STAT, Ras, and PI3K-Akt pathways. Securinine had a favorable binding affinity with HDAC1, HSP90AB, JAK2, PRMT5, PTGS2, and TERT. Securinine rescued viability suppression, mitochondria damage, and SMN loss in the SMA cell model. Furthermore, securinine increased HDAC1 and PRMT5 expression, decreased PTGS2 expression, suppressed the JAK2-STAT3 pathway, and promoted the PI3K-Akt pathway.

Conclusion: Securinine might alleviate SMA by elevating HDAC1 and PRMT5 expression and reducing PTGS2 via JAK2-STAT3 suppression and PI3K-Akt activation.

[1]
Ross LF, Kwon JM. Spinal muscular atrophy: Past, present, and future. Neoreviews 2019; 20(8): e437-51.
[http://dx.doi.org/10.1542/neo.20-8-e437] [PMID: 31371553]
[2]
Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers 2022; 8(1): 52.
[http://dx.doi.org/10.1038/s41572-022-00380-8] [PMID: 35927425]
[3]
Butterfield RJ. Spinal muscular atrophy treatments, newborn screening, and the creation of a neurogenetics urgency. Semin Pediatr Neurol 2021; 38: 100899.
[http://dx.doi.org/10.1016/j.spen.2021.100899] [PMID: 34183144]
[4]
Bozorg Qomi S, Asghari A, Salmaninejad A, Mojarrad M. Spinal muscular atrophy and common therapeutic advances. Fetal Pediatr Pathol 2019; 38(3): 226-38.
[http://dx.doi.org/10.1080/15513815.2018.1520374] [PMID: 31060440]
[5]
Aslesh T, Yokota T. Restoring SMN expression: An overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells 2022; 11(3): 417.
[http://dx.doi.org/10.3390/cells11030417] [PMID: 35159227]
[6]
James R, Chaytow H, Ledahawsky LM, Gillingwater TH. Revisiting the role of mitochondria in spinal muscular atrophy. Cell Mol Life Sci 2021; 78(10): 4785-804.
[http://dx.doi.org/10.1007/s00018-021-03819-5] [PMID: 33821292]
[7]
Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: Current knowledge and existing gaps. Dev Med Child Neurol 2019; 61(1): 19-24.
[http://dx.doi.org/10.1111/dmcn.14027] [PMID: 30221755]
[8]
Hoy SM. Onasemnogene abeparvovec: First global approval. Drugs 2019; 79(11): 1255-62.
[http://dx.doi.org/10.1007/s40265-019-01162-5] [PMID: 31270752]
[9]
Cleary Y, Gertz M, Grimsey P, et al. Model-based drug–drug interaction extrapolation strategy from adults to children: Risdiplam in pediatric patients with spinal muscular atrophy. Clin Pharmacol Ther 2021; 110(6): 1547-57.
[http://dx.doi.org/10.1002/cpt.2384] [PMID: 34347881]
[10]
Kang P, Wu Z, Zhong Y, et al. A network pharmacology and molecular docking strategy to explore potential targets and mechanisms underlying the effect of curcumin on osteonecrosis of the femoral head in systemic lupus erythematosus. BioMed Res Int 2021; 2021: 1-14.
[http://dx.doi.org/10.1155/2021/5538643] [PMID: 34557547]
[11]
Ullah R, Alqahtani AS. GC-MS Analysis, heavy metals, biological, and toxicological evaluation of Reseda muricata and Marrubium vulgare methanol extracts. Evid Based Complement Alternat Med 2022; 2022: 1-9.
[http://dx.doi.org/10.1155/2022/2284328] [PMID: 35356243]
[12]
Leonoudakis D, Rane A, Angeli S, Lithgow GJ, Andersen JK, Chinta SJ. Anti-inflammatory and neuroprotective role of natural product securinine in activated glial cells: Implications for Parkinson’s disease. Mediators Inflamm 2017; 2017: 1-11.
[http://dx.doi.org/10.1155/2017/8302636] [PMID: 28473732]
[13]
Zhang D, Liu H, Yang B, Hu J, Cheng Y. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways. Biosci Rep 2019; 39(5): BSR20190469.
[http://dx.doi.org/10.1042/BSR20190469] [PMID: 30975734]
[14]
Wu ZL, Huang XJ, Xu MT, et al. Flueggeacosines A–C, dimeric securinine-type alkaloid analogues with neuronal differentiation activity from Flueggea suffruticosa. Org Lett 2018; 20(23): 7703-7.
[http://dx.doi.org/10.1021/acs.orglett.8b03432] [PMID: 30484660]
[15]
Chen YC, Chang JG, Liu TY, Jong YJ, Cheng WL, Yuo CY. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells. Biomed Pharmacother 2017; 88: 708-14.
[http://dx.doi.org/10.1016/j.biopha.2017.01.104] [PMID: 28152480]
[16]
Yuan H, Ma Q, Cui H, et al. How can synergism of traditional medicines benefit from network pharmacology? Molecules 2017; 22(7): 1135.
[http://dx.doi.org/10.3390/molecules22071135] [PMID: 28686181]
[17]
Xu S, Wang L, Pan X. An evaluation of combined strategies for improving the performance of molecular docking. J Bioinform Comput Biol 2021; 19(2): 2150003.
[http://dx.doi.org/10.1142/S0219720021500037] [PMID: 33641636]
[18]
Yan D, Zheng G, Wang C, et al. HIT 2.0: An enhanced platform for herbal ingredients’. Nucleic Acids Res 2022; 50(D1): D1238-43.
[http://dx.doi.org/10.1093/nar/gkab1011] [PMID: 34986599]
[19]
Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007; 25(2): 197-206.
[http://dx.doi.org/10.1038/nbt1284] [PMID: 17287757]
[20]
Gallo K, Goede A, Preissner R, Gohlke BO. SuperPred 3.0: Drug classification and target prediction-a machine learning approach. Nucleic Acids Res 2022; 50(W1): W726-31.
[http://dx.doi.org/10.1093/nar/gkac297] [PMID: 35524552]
[21]
Bateman A, Martin M-J, Orchard S, et al. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res 2021; 49(D1): D480-9.
[http://dx.doi.org/10.1093/nar/gkaa1100] [PMID: 33237286]
[22]
Safran M, Dalah I, Alexander J, et al. GeneCards Version 3: The human gene integrator. Database (Oxford) 2010; 2010(0): baq020.
[http://dx.doi.org/10.1093/database/baq020] [PMID: 20689021]
[23]
Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 2020; 48(D1): D845-55.
[PMID: 31680165]
[24]
Franz M, Rodriguez H, Lopes C, et al. GeneMANIA update 2018. Nucleic Acids Res 2018; 46(W1): W60-4.
[http://dx.doi.org/10.1093/nar/gky311] [PMID: 29912392]
[25]
Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 2014; 8(S4) (Suppl. 4): S11.
[http://dx.doi.org/10.1186/1752-0509-8-S4-S11] [PMID: 25521941]
[26]
Chen L, Zhang YH, Wang S, Zhang Y, Huang T, Cai YD. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways. PLoS One 2017; 12(9): e0184129.
[http://dx.doi.org/10.1371/journal.pone.0184129] [PMID: 28873455]
[27]
Yang M, Chen J, Xu L, et al. A network pharmacology approach to uncover the molecular mechanisms of herbal formula Ban-Xia-Xie-Xin-Tang. Evid Based Complement Alternat Med 2018; 2018: 1-22.
[http://dx.doi.org/10.1155/2018/4050714] [PMID: 30410554]
[28]
Nicolau S, Waldrop MA, Connolly AM, Mendell JR. Spinal muscular atrophy. Semin Pediatr Neurol 2021; 37: 100878.
[http://dx.doi.org/10.1016/j.spen.2021.100878] [PMID: 33892848]
[29]
Barkats M. SMA: From gene discovery to gene therapy. Med Sci (Paris) 2020; 36(2): 137-40.
[http://dx.doi.org/10.1051/medsci/2020010] [PMID: 32129749]
[30]
Kwak SC, Jeong DH, Cheon YH, et al. Securinine suppresses osteoclastogenesis and ameliorates inflammatory bone loss. Phytother Res 2020; 34(11): 3029-40.
[http://dx.doi.org/10.1002/ptr.6735] [PMID: 32510717]
[31]
Klochkov S, Neganova M. Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs. RSC Adv 2021; 11(31): 19185-95.
[http://dx.doi.org/10.1039/D1RA02558A] [PMID: 35478659]
[32]
Liu CJ, Fan XD, Jiang JG, Chen QX, Zhu W. Potential anticancer activities of securinine and its molecular targets. Phytomedicine 2022; 106: 154417.
[http://dx.doi.org/10.1016/j.phymed.2022.154417] [PMID: 36063584]
[33]
Xiao H, Zhang Q, Zhong P, et al. Securinine promotes neuronal development and exhibits antidepressant-like effects via mtor activation. ACS Chem Neurosci 2021; 12(19): 3650-61.
[http://dx.doi.org/10.1021/acschemneuro.1c00381] [PMID: 34541857]
[34]
Hou W, Huang H, Wu XQ, Lan JX. Bioactivities and mechanism of action of securinega alkaloids derivatives reported prior to 2022. Biomed Pharmacother 2023; 158: 114190.
[http://dx.doi.org/10.1016/j.biopha.2022.114190] [PMID: 36916441]
[35]
Beutler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR, Enna SJ. Securinine alkaloids: A new class of GABA receptor antagonist. Brain Res 1985; 330(1): 135-40.
[http://dx.doi.org/10.1016/0006-8993(85)90014-9] [PMID: 2985189]
[36]
Shipman M, Lubick K, Fouchard D, et al. Proteomic and systems biology analysis of monocytes exposed to securinine, a GABA(A) receptor antagonist and immune adjuvant. PLoS One 2012; 7(9): e41278.
[http://dx.doi.org/10.1371/journal.pone.0041278] [PMID: 23028424]
[37]
Abdelkader HA, Amin I, Rashed LA, Samir M, Ezzat M. Histone deacetylase 1 in patients with Alopecia areata and Acne vulgaris: An epigenetic alteration. Australas J Dermatol 2022; 63(2): e138-41.
[http://dx.doi.org/10.1111/ajd.13784] [PMID: 35076083]
[38]
Smalley JP, Baker IM, Pytel WA, et al. Optimization of class I histone deacetylase PROTACs reveals that HDAC1/2 degradation is critical to induce apoptosis and cell arrest in cancer cells. J Med Chem 2022; 65(7): 5642-59.
[http://dx.doi.org/10.1021/acs.jmedchem.1c02179] [PMID: 35293758]
[39]
Pagliarini V, Guerra M, Di Rosa V, Compagnucci C, Sette C. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in spinal muscular atrophy cells. J Neurochem 2020; 153(2): 264-75.
[http://dx.doi.org/10.1111/jnc.14935] [PMID: 31811660]
[40]
Liimatainen K, Huttunen R, Latonen L, Ruusuvuori P. Convolutional neural network-based artificial intelligence for classification of protein localization patterns. Biomolecules 2021; 11(2): 264.
[http://dx.doi.org/10.3390/biom11020264] [PMID: 33670112]
[41]
Wu S, Li YL, Cheng NY, et al. c.835-5T>G Variant in SMN1 gene causes transcript exclusion of Exon 7 and Spinal muscular atrophy. J Mol Neurosci 2018; 65(2): 196-202.
[http://dx.doi.org/10.1007/s12031-018-1079-1] [PMID: 29799103]
[42]
Day JW, Howell K, Place A, et al. Advances and limitations for the treatment of spinal muscular atrophy. BMC Pediatr 2022; 22(1): 632.
[http://dx.doi.org/10.1186/s12887-022-03671-x] [PMID: 36329412]
[43]
Reilly A, Chehade L, Kothary R. Curing SMA: Are we there yet? Gene Ther 2023; 30(1-2): 8-17.
[http://dx.doi.org/10.1038/s41434-022-00349-y] [PMID: 35614235]
[44]
Janzen E, Mendoza-Ferreira N, Hosseinibarkooie S, et al. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. Brain 2018; 141(8): 2343-61.
[http://dx.doi.org/10.1093/brain/awy167] [PMID: 29961886]
[45]
Berciano MT, Castillo-Iglesias MS, Val-Bernal JF, et al. Mislocalization of SMN from the I-band and M-band in human skeletal myofibers in spinal muscular atrophy associates with primary structural alterations of the sarcomere. Cell Tissue Res 2020; 381(3): 461-78.
[http://dx.doi.org/10.1007/s00441-020-03236-3] [PMID: 32676861]
[46]
McLeod VM, Chiam MDF, Lau CL, Rupasinghe TW, Boon WC, Turner BJ. Dysregulation of steroid hormone receptors in motor neurons and glia associates with disease progression in ALS Mice. Endocrinology 2020; 161(9): bqaa113.
[http://dx.doi.org/10.1210/endocr/bqaa113] [PMID: 32621747]
[47]
Wan B, Feng P, Guan Z, Sheng L, Liu Z, Hua Y. A severe mouse model of spinal muscular atrophy develops early systemic inflammation. Hum Mol Genet 2018; 27(23): 4061-76.
[http://dx.doi.org/10.1093/hmg/ddy300] [PMID: 30137324]
[48]
Thomas EA, D’Mello SR. Complex neuroprotective and neurotoxic effects of histone deacetylases. J Neurochem 2018; 145(2): 96-110.
[http://dx.doi.org/10.1111/jnc.14309] [PMID: 29355955]
[49]
Lai JI, Leman LJ, Ku S, et al. Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells. Bioorg Med Chem Lett 2017; 27(15): 3289-93.
[http://dx.doi.org/10.1016/j.bmcl.2017.06.027] [PMID: 28648462]
[50]
Raffaele S, Lombardi M, Verderio C, Fumagalli M. TNF production and release from microglia via extracellular vesicles: Impact on brain functions. Cells 2020; 9(10): 2145.
[http://dx.doi.org/10.3390/cells9102145] [PMID: 32977412]
[51]
Hanna A, Frangogiannis NG. Inflammatory cytokines and chemokines as therapeutic targets in heart failure. Cardiovasc Drugs Ther 2020; 34(6): 849-63.
[http://dx.doi.org/10.1007/s10557-020-07071-0] [PMID: 32902739]
[52]
Ando S, Osanai D, Takahashi K, Nakamura S, Shimazawa M, Hara H. Survival motor neuron protein regulates oxidative stress and inflammatory response in microglia of the spinal cord in spinal muscular atrophy. J Pharmacol Sci 2020; 144(4): 204-11.
[http://dx.doi.org/10.1016/j.jphs.2020.09.001] [PMID: 33070839]
[53]
Yin Q, Wang L, Yu H, Chen D, Zhu W, Sun C. Pharmacological effects of polyphenol phytochemicals on the JAK-STAT signaling pathway. Front Pharmacol 2021; 12: 716672.
[http://dx.doi.org/10.3389/fphar.2021.716672] [PMID: 34539403]
[54]
Yan Z, Gibson SA, Buckley JA, Qin H, Benveniste EN. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol 2018; 189: 4-13.
[http://dx.doi.org/10.1016/j.clim.2016.09.014] [PMID: 27713030]
[55]
Dai J, Xu LJ, Han GD, et al. MicroRNA-125b promotes the regeneration and repair of spinal cord injury through regulation of JAK/STAT pathway. Eur Rev Med Pharmacol Sci 2018; 22(3): 582-9.
[PMID: 29461585]
[56]
Yoshino H, Yin G, Kawaguchi R, et al. Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One 2019; 14(8): e0219436.
[http://dx.doi.org/10.1371/journal.pone.0219436] [PMID: 31390367]
[57]
Pompura SL, Dominguez-Villar M. The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol 2018; 103(6): 1065-76.
[http://dx.doi.org/10.1002/JLB.2MIR0817-349R] [PMID: 29357116]
[58]
Sansa A, de la Fuente S, Comella JX, Garcera A, Soler RM. Intracellular pathways involved in cell survival are deregulated in mouse and human spinal muscular atrophy motoneurons. Neurobiol Dis 2021; 155: 105366.
[http://dx.doi.org/10.1016/j.nbd.2021.105366] [PMID: 33845129]
[59]
Chen JS, Wang HK, Hsu CY, et al. HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis. Sci Rep 2021; 11(1): 16354.
[http://dx.doi.org/10.1038/s41598-021-95837-3] [PMID: 34381129]
[60]
Kumar V, Kundu S, Singh A, Singh S. Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: Current targets and future perspective. Curr Neuropharmacol 2022; 20(1): 158-78.
[http://dx.doi.org/10.2174/1570159X19666210609160017] [PMID: 34151764]
[61]
Tao CC, Hsu WL, Ma YL, Cheng SJ, Lee EHY. Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against Aβ toxicity in a mouse model of Alzheimer’s disease. Cell Death Differ 2017; 24(4): 597-614.
[http://dx.doi.org/10.1038/cdd.2016.161] [PMID: 28186506]
[62]
Zhang H, Yin X, Zhang X, et al. HSP90AB1 promotes the proliferation, migration, and glycolysis of head and neck squamous cell carcinoma. Technol Cancer Res Treat 2022; 21
[http://dx.doi.org/10.1177/15330338221118202] [PMID: 35929142]
[63]
Siebert A, Gattringer V, Weishaupt JH, Behrends C. ALS-linked loss of Cyclin-F function affects HSP90. Life Sci Alliance 2022; 5(12): e202101359.
[http://dx.doi.org/10.26508/lsa.202101359] [PMID: 36114006]
[64]
Gonzalez-Rodriguez M, Villar-Conde S, Astillero-Lopez V, et al. Neurodegeneration and astrogliosis in the human CA1 hippocampal subfield are related to hsp90ab1 and bag3 in Alzheimer’s disease. Int J Mol Sci 2021; 23(1): 165.
[http://dx.doi.org/10.3390/ijms23010165] [PMID: 35008592]
[65]
Zhu H, Jian Z, Zhong Y, et al. Janus kinase inhibition ameliorates ischemic stroke injury and neuroinflammation through reducing NLRP3 inflammasome activation via JAK2/STAT3 pathway inhibition. Front Immunol 2021; 12: 714943.
[http://dx.doi.org/10.3389/fimmu.2021.714943] [PMID: 34367186]
[66]
Xu M, Ni H, Xu L, et al. B14 ameliorates bone cancer pain through downregulating spinal interleukin-1β via suppressing neuron JAK2/STAT3 pathway. Mol Pain 2019; 15
[http://dx.doi.org/10.1177/1744806919886498] [PMID: 31615322]
[67]
Xiong J, Zhou H, Lu D, et al. Levetiracetam Reduces early inflammatory response after experimental intracerebral hemorrhage by regulating the Janus Kinase 2 (JAK2)–Signal Transducer and Activator of Transcription 3 (STAT3) signaling pathway. Med Sci Monit 2020; 26: e922741.
[http://dx.doi.org/10.12659/MSM.922741] [PMID: 32289810]
[68]
Yang H, Wang H, Shu Y, Li X. miR-103 promotes neurite outgrowth and suppresses cells apoptosis by targeting prostaglandin-endoperoxide synthase 2 in cellular models of Alzheimer’s disease. Front Cell Neurosci 2018; 12: 91.
[http://dx.doi.org/10.3389/fncel.2018.00091] [PMID: 29674956]
[69]
Zhuang J, Chen Z, Cai P, et al. Targeting MicroRNA-125b Promotes neurite outgrowth but represses cell apoptosis and inflammation via blocking PTGS2 and CDK5 in a FOXQ1-dependent way in Alzheimer disease. Front Cell Neurosci 2020; 14: 587747.
[http://dx.doi.org/10.3389/fncel.2020.587747] [PMID: 33408612]
[70]
Chen Y, Shao X, Zhao X, et al. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms. Biomed Pharmacother 2021; 144: 112252.
[http://dx.doi.org/10.1016/j.biopha.2021.112252] [PMID: 34619493]
[71]
Yuan Y, Nie H. Protein arginine methyltransferase 5: A potential cancer therapeutic target. Cell Oncol (Dordr) 2021; 44(1): 33-44.
[http://dx.doi.org/10.1007/s13402-020-00577-7] [PMID: 33469838]
[72]
Lanfranco M, Vassallo N, Cauchi RJ. Spinal muscular atrophy: From defective chaperoning of snRNP assembly to neuromuscular dysfunction. Front Mol Biosci 2017; 4: 41.
[http://dx.doi.org/10.3389/fmolb.2017.00041] [PMID: 28642865]
[73]
Shim HS, Horner JW, Wu CJ, et al. Telomerase reverse transcriptase preserves neuron survival and cognition in Alzheimer’s disease models. Nature Aging 2021; 1(12): 1162-74.
[http://dx.doi.org/10.1038/s43587-021-00146-z] [PMID: 35036927]
[74]
McKelvey BA, Umbricht CB, Zeiger MA. Telomerase Reverse Transcriptase (TERT) regulation in thyroid cancer: A review. Front Endocrinol (Lausanne) 2020; 11: 485.
[http://dx.doi.org/10.3389/fendo.2020.00485] [PMID: 32849278]
[75]
Zou Y, Cong Y, Zhou J. Implications of telomerase reverse transcriptase in tumor metastasis. BMB Rep 2020; 53(9): 458-65.
[http://dx.doi.org/10.5483/BMBRep.2020.53.9.108] [PMID: 32731912]
[76]
Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochim Biophys Acta Gene Regul Mech 2017; 1860(3): 299-315.
[http://dx.doi.org/10.1016/j.bbagrm.2016.12.008] [PMID: 28095296]